The path to diagnosing coronary artery disease (CAD) hasn’t always been clear or reliable.1,2 Until now.
The CT-Flow pathway enables physicians to more accurately diagnose patients with suspected CAD by combining two powerful, non-invasive technologies — coronary CTA (CCTA) and the HeartFlow Analysis.1
To address the current gaps in cardiac diagnostic testing, the CT-Flow pathway:
Choosing the appropriate diagnostic test for your patient depends on the questions you are trying to answer and the information the test will provide. Use this chart to help determine which test is best for your patient.
|SPECT||Stress Echo||Coronary CTA||HeartFlow Analysis|
|Does my patient have CAD?||X||X||X||X|
|Do the vessels have plaque?||X||X|
|Where are the coronary artery speciﬁc stenoses?||X||X|
|Is there possible ischemia?||X||X||X|
|What are the lesion-speciﬁc functional limitations?||X|
|Which vessels may beneﬁt from PCI/CABG/OMT?||X|
|Is prognostic information provided?||X||X||X||X|
high rate of false negatives; higher radiation exposure;
lacks anatomic data
lacks anatomic data
High sensitivity can lead to overutilization of invasive
when not paired with
Currently not as well known as other tests
standard of care
usual care testing;
provides anatomic data
More accurate than|
other non-invasive tests;
provides anatomic and
lower radiation; single
* Diagnostic performance of SPECT, CCTA and FFRCT evaluated in a head-to-head comparison for the identification of ischaemia.
Click to expand
The CT-Flow pathway provides the highest diagnostic performance available from a non-invasive test to help identify functional disease.1,2 This pathway leads to targeted treatment plans and a more streamlined patient experience.
Physicians can use the CT-Flow pathway for any clinically stable symptomatic patient with CAD. The pathway requires access to a standard CT scanner and an institution that offers the HeartFlow Analysis. Find a center near you using our finder tool or contact your local HeartFlow representative.
Within hours, physicians can receive the HeartFlow Analysis, which is available on desktop and mobile.
CT-Flow offers a streamlined workflow that reduces unnecessary invasive testing and radiation exposure, and provides more accurate information about their condition compared to other non-invasive cardiac tests.1,2,3,4 The highly visual, color-coded model resonates well with patients and can help increase adherence to treatment plans.
Both CCTA and the HeartFlow Analysis, the two steps of the CT-Flow pathway, are commercially available. The HeartFlow Analysis is FDA cleared and reimbursed by CMS and most major commercial insurers. It’s currently available at more than 200 institutions worldwide — in the United States, United Kingdom, Europe, Canada and Japan — and has been used for more than 40,000 patients to date.
* Required fields
1 Driessen, et al. J Am Coll Cardiol 2019; Norgaard, et al, Euro J Radiol 2015.
2 Melikian, et al. JACC: Cardiovasc Interv 2010; Jung, et al. Euro Heart J 2008. Koo, et al. J Am Coll; Cardiol 2011. Min, et al. JAMA 2012. Nørgaard, et al. J Am Coll Cardiol 2014.
3 Patel, et al. J Am Coll Cardiol 2019.
4 Stocker, et al. Euro Heart J 2018.
5 Curzen, N.P., et al., J Am Coll Cardiol 2016. Newby D.E., et al. N Engl J Med 2018.
6 Danad, et al., Euro Heart J 2017.